These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 25547357

  • 1. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.
    Sato M, Ito M, Suzuki S, Sakuma H, Takeyama A, Oda S, Watanabe M, Hashimoto K, Miyazaki K, Kawasaki Y, Hosoya M.
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1643-9. PubMed ID: 25547357
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
    Saisho Y, Ishibashi T, Fukuyama H, Fukase H, Shimada J.
    Antivir Ther; 2017 Mar; 22(4):313-323. PubMed ID: 27805571
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.
    Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T.
    Antimicrob Agents Chemother; 2012 Jan; 56(1):369-77. PubMed ID: 22024821
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
    Barroso L, Treanor J, Gubareva L, Hayden FG.
    Antivir Ther; 2005 Jan; 10(8):901-10. PubMed ID: 16430195
    [Abstract] [Full Text] [Related]

  • 5. Peramivir clearance in continuous renal replacement therapy.
    Thomas B, Hollister AS, Muczynski KA.
    Hemodial Int; 2010 Jul; 14(3):339-40. PubMed ID: 20491974
    [No Abstract] [Full Text] [Related]

  • 6. Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series.
    Cies JJ, Moore WS, Enache A, Chopra A.
    Pharmacotherapy; 2019 Nov; 39(11):1060-1065. PubMed ID: 31514223
    [Abstract] [Full Text] [Related]

  • 7. Optimizing antiviral therapy for influenza: understanding the evidence.
    Ison MG.
    Expert Rev Anti Infect Ther; 2015 Apr; 13(4):417-25. PubMed ID: 25695406
    [Abstract] [Full Text] [Related]

  • 8. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.
    Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA.
    Antiviral Res; 2008 Nov; 80(2):150-7. PubMed ID: 18573280
    [Abstract] [Full Text] [Related]

  • 9. Immune response after a single intravenous peramivir administration in children with influenza.
    Sato M, Hashimoto K, Kawasaki Y, Hosoya M.
    Antivir Ther; 2018 Nov; 23(5):435-441. PubMed ID: 29372885
    [Abstract] [Full Text] [Related]

  • 10. Peramivir for the treatment of influenza.
    Shetty AK, Peek LA.
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Kobayashi M, Kodama M, Noshi T, Yoshida R, Kanazu T, Nomura N, Soda K, Isoda N, Okamatsu M, Sakoda Y, Yamano Y, Sato A, Kida H.
    Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
    [Abstract] [Full Text] [Related]

  • 12. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials.
    Whitley R, Laughlin A, Carson S, Mitha E, Tellier G, Stich M, Elder J, Alexander WJ, Dobo S, Collis P, Sheridan WP.
    Antivir Ther; 2015 Mar; 20(7):709-19. PubMed ID: 25318121
    [Abstract] [Full Text] [Related]

  • 13. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.
    Arya V, Carter WW, Robertson SM.
    Clin Pharmacol Ther; 2010 Nov; 88(5):587-9. PubMed ID: 20959843
    [Abstract] [Full Text] [Related]

  • 14. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
    Onishi M, Kitano M, Taniguchi K, Homma T, Kobayashi M, Yoshinaga T, Naito A, Sato A.
    Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738
    [Abstract] [Full Text] [Related]

  • 15. Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.
    Bentley ML, Hollistera AS, Hansenb AC, Smith JA, Cain JS.
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1105-11. PubMed ID: 25345428
    [Abstract] [Full Text] [Related]

  • 16. The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice.
    Kodama M, Yoshida R, Hasegawa T, Izawa M, Kitano M, Baba K, Noshi T, Seki T, Okazaki K, Tsuji M, Kanazu T, Kamimori H, Homma T, Kobayashi M, Sakoda Y, Kida H, Sato A, Yamano Y.
    Antiviral Res; 2014 Sep; 109():110-5. PubMed ID: 24997412
    [Abstract] [Full Text] [Related]

  • 17. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H.
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [Abstract] [Full Text] [Related]

  • 18. Intravenous peramivir for treatment of influenza in hospitalized patients.
    Ison MG, Fraiz J, Heller B, Jauregui L, Mills G, O'Riordan W, O'Neil B, Playford EG, Rolf JD, Sada-Diaz E, Elder J, Collis P, Hernandez JE, Sheridan WP.
    Antivir Ther; 2014 Sep; 19(4):349-61. PubMed ID: 23985625
    [Abstract] [Full Text] [Related]

  • 19. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.
    Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, Shimada J, S-021812 Clinical Study Group.
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2803-12. PubMed ID: 21464252
    [Abstract] [Full Text] [Related]

  • 20. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation.
    Komeda T, Ishii S, Itoh Y, Ariyasu Y, Sanekata M, Yoshikawa T, Shimada J.
    J Infect Chemother; 2015 Mar; 21(3):194-201. PubMed ID: 25523716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.